4.5 Article

Estimated costs for Duchenne muscular dystrophy care in Brazil

Journal

ORPHANET JOURNAL OF RARE DISEASES
Volume 18, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13023-023-02767-6

Keywords

Cost of illness; Muscular dystrophy; Duchenne; Neuromuscular diseases; Rare diseases

Ask authors/readers for more resources

This study evaluates the annual costs of hospital, home care, and transportation for patients with DMD in Brazil. The results show that home care expenditures account for 92% of the total costs, followed by hospital costs (6%) and transportation costs (2%). Accurate information about costs is crucial for establishing sustainable health policies for rare diseases.
BackgroundThe economic burden of rare diseases on health systems is still not widely measured, with the generation of accurate information about the costs with medical care for subjects with rare diseases being crucial when defining health policies. Duchenne Muscular Dystrophy (DMD) is the most common form of muscular dystrophy, with new technologies recently being studied for its management. Information about the costs related to the disease in Latin America is scarce, and the objective of this study is to evaluate the annual hospital, home care and transportation costs per patient with DMD treatment in Brazil.ResultsData from 27 patients were included, the median annual cost per patient was R$ 17,121 (IQR R$ 6,786; 25,621). Home care expenditures accounted for 92% of the total costs, followed by hospital costs (6%) and transportation costs (2%). Medications and loss of family, and patient's productivity are among the most representative consumption items. When disease worsening due to loss of the ability to walk was incorporated to the analysis, it was shown that wheelchair users account for an incremental cost of 23% compared with non-wheelchair users.ConclusionsThis is an original study in Latin America to measure DMD costs using the micro-costing technique. Generating accurate information about costs is crucial to provide health managers with information that could help establish more sustainable policies when deciding upon rare diseases in emerging countries.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available